Adma Biologics Inc
ADMA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.16B
Close$
$7.07
24.2% downside
Current Fair Value
24.2% downsideOvervalued by 24.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.16 Billion |
|---|---|
| Enterprise Value | $2.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.62 |
| Beta | 0.77 |
| Outstanding Shares | 228,232,503 |
Return
| Return on Equity | 41.39% |
|---|---|
| Return on Assets | 24.69% |
| Return on Invested Capital | 37.17% |
Valuation & Multiples
| P/E Ratio | 12.97 |
|---|---|
| PEG | 123.2 |
| Price to Sales | 4.67 |
| Price to Book Ratio | 9.33 |
| Enterprise Value to Revenue | 4.36 |
| Enterprise Value to EBIT | 9.87 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.5 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$149.08 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.19
Average shareholder expectationRevenue Estimate
$138.12 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6557▲ 30.80% |
|---|---|
| Total Calls | 2,418,610▼ 62.48% |
| Total Puts | 1,585,800▼ 29.24% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 87.79%▼ 1.95% |
|---|---|
| Total Invested | $1.97B▲ 2.98% |
| Investors Holding | 341▼ 32.00% |
ESG Score
No data